Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer A. Woyach, Paul M. Barr et al.|American Journal of Hematology|2019Cited by 472
Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPaul M. Barr, Susan O’Brien, Alessandra Tedeschi et al.|Blood|2019Cited by 2